Anticancer Drug Market, By Route of Administration (Intravenous (IV), Subcutaneous, Oral, and Topical / Localized), By Drug Class, By Indication, By Distribution Channels, By Dosage Form, By End-Users, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4498
|
Published Date
November 2025
|
Pages
398
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
Anticancer Drug Market size was valued at US$ 166,669.56 Million in 2024, expanding at a CAGR of 9.5% from 2025 to 2032.
Anticancer drugs—also called antineoplastic agents—are medications that inhibit the growth and spread of malignant cells. Their global market is expanding rapidly, propelled by the rising incidence of cancer worldwide and increasing government and private-sector investment in oncology research. For instance, between 2016 and 2023, public and philanthropic funding for cancer research reached approximately US$ 51.4 billion, with governments (especially in the U.S. and Europe) providing the bulk of this support.
In the United States, the National Cancer Institute’s (NCI) budget has grown steadily: its total funding rose from US$ 5.93 billion in 2018 to about US$ 7.22 billion in 2024. Meanwhile, multilateral bodies such as the International Agency for Research on Cancer (IARC) receive contributions from member states, with the IARC regular budget for 2024–2025 set at €48.68 million.
Despite this robust investment, the high cost of anticancer treatments and stringent regulatory approval processes continue to restrict access, especially in low- and middle-income countries. Nevertheless, the market offers significant opportunities: breakthroughs in immunotherapy and precision oncology—fueled by genetic profiling and biomarker-based strategies—are enabling more effective and less toxic therapies. Continued innovation in biologic drugs and combination therapies is expected to drive substantial market growth in the years to come.
Anticancer Drug Market- Market Dynamics
Rising Cancer Prevalence to Drive Market Growth
The rising global incidence of cancer is a major factor driving the growth of the anticancer drug market. Aging populations, lifestyle changes, environmental pollution, and genetic predispositions are all contributing to the steady increase in cancer cases worldwide. As the patient population expands, so does the demand for advanced treatment options, including targeted therapies, immunotherapies, and personalized medicines. This growing need is prompting pharmaceutical companies to boost their R&D investments and accelerate the development of innovative therapeutics aimed at improving patient outcomes. According to the World Health Organization (WHO), new cancer cases are projected to rise from 18.1 million in 2018 to 29.4 million by 2040, underscoring the urgent need for next-generation anticancer drugs and reinforcing strong market growth prospects over the forecast period.
Anticancer Drug Market- Segmentation Analysis:
The Global Anticancer Drug Market is segmented on the basis of Route of Administration, Drug Class, Indication, Distribution Channels, Dosage Form, End-Users, and Region.
The Anticancer Drug Market is segmented by dosage form into Solid (tablets and capsules), Injectable (prefilled syringes and others), Liquid, and Other formulations. Among these, the injectable segment represents a major revenue contributor, largely due to the increasing use of biologics and targeted therapies that require parenteral administration for optimal efficacy and controlled release. In oncology, injectable drugs are preferred because they ensure precise dosing, rapid systemic absorption, and improved therapeutic outcomes when administered under medical supervision. Additionally, the expanding availability of biosimilars and generic injectable formulations is enhancing accessibility and contributing to market growth. For example, in September 2020, Mylan N.V. launched Fulvestrant Injection (250 mg/5 mL) in the United States—a generic version of AstraZeneca’s Faslodex used to treat certain forms of advanced breast cancer—demonstrating continued innovation and active competition within the injectable segment.
From a drug class perspective, targeted therapy remains one of the most influential segments in the anticancer drug market due to its ability to selectively attack malignant cells while sparing healthy tissues, thereby improving therapeutic outcomes and reducing toxicity. This precision-based approach acts directly on specific molecular pathways involved in cancer progression, making it more effective and better tolerated than traditional chemotherapy. The expanding pipeline of FDA-approved monoclonal antibodies, kinase inhibitors, and immune-modulating agents reflects significant scientific advancement in oncology. Furthermore, the integration of genomic testing and companion diagnostics is enhancing treatment accuracy and enabling more personalized cancer care. Rising regulatory approvals for innovative targeted therapies, along with a robust pipeline of investigational drugs, continues to strengthen segment growth. For instance, in June 2023, the U.S. FDA approved the combination of dabrafenib and trameti
Anticancer Drug Market- Geographical Insights
The Anticancer Drug Market demonstrates significant regional variation, influenced by differences in healthcare infrastructure, cancer incidence, and access to advanced therapies. The Asia-Pacific region remains one of its fastest-growing markets, accounting for roughly 20% of the global share. Growth here is driven by a rising cancer burden, increasing healthcare expenditure, and broader access to modern oncology treatments. Rapid urbanization, lifestyle transitions, and an aging population are contributing to the rising prevalence of cancer.
In response, governments across Asia-Pacific—especially in China, India, and Japan—are making substantial investments in oncology research, clinical trials, and healthcare infrastructure. For example, public spending on cancer drugs in Asia-Pacific ranges widely: high-income markets in the region reportedly spent 10–20% of their total pharmaceutical budget on cancer drugs, whereas middle-income markets spent around 1–9%. In India, the government’s 2025–26 health budget has earmarked funds to expand cancer care: new Day Care Cancer Centres are being planned at district hospitals, and 36 cancer, rare-disease, and chronic-disease drugs have been exempted from basic customs duty to reduce treatment costs. On a global scale, this supportive policy environment—coupled with rising patient awareness and better reimbursement mechanisms—is making it easier for novel therapies such as targeted drugs, immunotherapies, and combination regimens to penetrate the market.
China Anticancer Drug Market- Country Insights
China’s large population, rising cancer incidence, and rapidly expanding healthcare infrastructure position it as a major growth driver in the Asia-Pacific anticancer drug market. According to the World Health Organization, China is projected to record approximately 4.3 million new cancer cases in 2025, with lung, breast, and colorectal cancers being the most prevalent. In response, the Chinese government is making significant investments in oncology research, clinical trial expansion, and the development of advanced hospital networks. Growing public awareness, wider access to innovative therapies—including targeted treatments and immunotherapies—and increasingly supportive reimbursement policies are accelerating the adoption of modern anticancer drugs. These developments collectively reinforce China’s role as a dominant and fast-growing market within the region.
Anticancer Drug Market- Competitive Landscape:
Roche Holding AG, Novartis AG, Bristol-Myers Squibb Company, Pfizer Inc., Merck & Co., Inc., AstraZeneca plc, and Johnson & Johnson are among the leading players in the anticancer drug market. These companies continue to intensify competition through advancements in targeted therapies, immuno-oncology, and precision medicine. The growing adoption of checkpoint inhibitors, CAR-T cell therapies, and antibody–drug conjugates (ADCs) is reshaping treatment standards and driving substantial R&D investments. To strengthen their oncology portfolios and expand global reach, industry leaders are increasingly engaging in strategic collaborations, mergers, and acquisitions. Additionally, the integration of AI-enabled drug discovery and biomarker-driven patient selection is accelerating the development of next-generation cancer therapies. As the global cancer burden rises, the competitive landscape is defined by rapid technological progress, expansion of clinical research, and a strong shift toward personalized, cost-effective treatment solutions.
Recent Developments:
- October 2025: AstraZeneca and Daiichi Sankyo announced that Datroway, a precision oncology drug, demonstrated improved survival outcomes in patients with advanced breast cancer in a late-stage clinical trial. This milestone is expected to support broader regulatory approvals and contribute to future market growth.
- June 2025: Bristol Myers Squibb entered into an $11 billion strategic collaboration with BioNTech to co-develop and commercialize BioNTech’s investigational bispecific antibody, BNT327, targeting multiple solid tumors. BioNTech received an upfront payment of $1.5 billion, with additional non-contingent anniversary payments through 2028 and potential milestone payments totaling up to $7.6 billion. This partnership represents a major commitment to advancing innovative immuno-oncology therapies and accelerating the clinical development of BNT327 across various indications.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis
- Pfizer
- Merck & Co. (MSD)
- Bristol Myers Squibb (BMS)
- AstraZeneca
- Roche/Genentech
- Johnson & Johnson/Janssen
- Sanofi
- Eli Lilly & Co.
- Takeda
- Amgen
- BeiGene
- Regeneron
- Bluebird Bio
- Seagen
- Moderna
- Genmab
- Incyte
- Exelixis
- Hutchmed / Chi-Med
- Others
GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous (IV)
- Subcutaneous
- Oral
- Topical / Localized
GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy
- Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
- Monoclonal Antibodies / Biologics
- Hormone Therapy
- Targeted Therapy
- Others (Oncolytic viruses, combination therapies, adjuncts)
GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Blood Cancer
- Gynaecologic Cancer
- Others
GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
- Solid (Tablets, Capsule)
- Injectable (Prefilled Syringes, Others)
- Liquid
- Others
GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Specialty Clinics
- Hospitals
- Homecare
- Others
GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. Anticancer Drug Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Anticancer Drug Market Snippet by Route of Administration
2.1.2. Anticancer Drug Market Snippet by Drug Class
2.1.3. Anticancer Drug Market Snippet by Indication
2.1.4. Anticancer Drug Market Snippet by Distribution Channels
2.1.5. Anticancer Drug Market Snippet by Dosage Form
2.1.6. Anticancer Drug Market Snippet by End-Users
2.1.7. Anticancer Drug Market Snippet by Country
2.1.8. Anticancer Drug Market Snippet by Region
2.2. Competitive Insights
3. Anticancer Drug Key Market Trends
3.1. Anticancer Drug Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Anticancer Drug Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Anticancer Drug Market Opportunities
3.4. Anticancer Drug Market Future Trends
4. Anticancer Drug Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Anticancer Drug Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Anticancer Drug Market Landscape
6.1. Anticancer Drug Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Anticancer Drug Market – By Route of Administration
7.1. Overview
7.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
7.1.2. Intravenous (IV)
7.1.3. Subcutaneous
7.1.4. Oral
7.1.5. Topical / Localized
8. Anticancer Drug Market – By Drug Class
8.1. Overview
8.1.1. Segment Share Analysis, By Drug Class, 2024 & 2032 (%)
8.1.2. Chemotherapy
8.1.3. Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
8.1.4. Monoclonal Antibodies / Biologics
8.1.5. Hormone Therapy
8.1.6. Targeted Therapy
8.1.7. Others (Oncolytic viruses, combination therapies, adjuncts)
9. Anticancer Drug Market – By Indication
9.1. Overview
9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
9.1.2. Breast Cancer
9.1.3. Lung Cancer
9.1.4. Prostate Cancer
9.1.5. Gastrointestinal Cancer
9.1.6. Blood Cancer
9.1.7. Gynaecologic Cancer
9.1.8. Others
10. Anticancer Drug Market – By Distribution Channels
10.1. Overview
10.1.1. Segment Share Analysis, By Distribution Channels, 2024 & 2032 (%)
10.1.2. Online Pharmacy
10.1.3. Hospital Pharmacy
10.1.4. Retail Pharmacy
11. Anticancer Drug Market – By Dosage Form
11.1. Overview
11.1.1. Segment Share Analysis, By Dosage Form, 2024 & 2032 (%)
11.1.2. Solid (Tablets, Capsule)
11.1.3. Injectable (Prefilled Syringes, Others)
11.1.4. Liquid
11.1.5. Others
12. Anticancer Drug Market – By End-Users
12.1. Overview
12.1.1. Segment Share Analysis, By End-Users, 2024 & 2032 (%)
12.1.2. Specialty Clinics
12.1.3. Hospitals
12.1.4. Homecare
12.1.5. Others
13. Anticancer Drug Market– By Geography
13.1. Introduction
13.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
13.2. North America
13.2.1. Overview
13.2.2. Anticancer Drug Key Manufacturers in North America
13.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.2.4. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.2.5. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.2.7. North America Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.2.8. North America Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.2.9. North America Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.2.10. U.S.
13.2.10.1. Overview
13.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.2.10.3. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.2.10.4. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.2.10.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.2.10.6. U.S. Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.2.10.7. U.S. Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.2.10.8. U.S. Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.2.11. Canada
13.2.11.1. Overview
13.2.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.2.11.3. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.2.11.4. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.2.11.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.2.11.6. Canada Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.2.11.7. Canada Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.2.11.8. Canada Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3. Europe
13.3.1. Overview
13.3.2. Anticancer Drug Key Manufacturers in Europe
13.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.3.4. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.5. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.7. Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.8. Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.9. Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.10. Germany
13.3.10.1. Overview
13.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.10.3. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.10.4. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.10.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.10.6. Germany Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.10.7. Germany Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.10.8. Germany Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.11. UK
13.3.11.1. Overview
13.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.11.3. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.11.4. UK Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.11.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.11.6. UK Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.11.7. UK Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.11.8. UK Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.12. France
13.3.12.1. Overview
13.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.12.3. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.12.4. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.12.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.12.6. France Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.12.7. France Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.12.8. France Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.13. Italy
13.3.13.1. Overview
13.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.13.3. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.13.4. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.13.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.13.6. Italy Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.13.7. Italy Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.13.8. Italy Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.14. Spain
13.3.14.1. Overview
13.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.14.3. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.14.4. Spain Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.14.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.14.6. Spain Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.14.7. Spain Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.14.8. Spain Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.15. The Netherlands
13.3.15.1. Overview
13.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.15.3. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.15.4. The Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.15.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.15.6. The Netherlands Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.15.7. The Netherlands Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.15.8. The Netherlands Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.16. Sweden
13.3.16.1. Overview
13.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.16.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.16.4. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.16.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.16.6. Sweden Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.16.7. Sweden Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.16.8. Sweden Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.17. Russia
13.3.17.1. Overview
13.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.17.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.17.4. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.17.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.17.6. Russia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.17.7. Russia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.17.8. Russia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.18. Poland
13.3.18.1. Overview
13.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.18.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.18.4. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.18.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.18.6. Poland Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.18.7. Poland Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.18.8. Poland Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.3.19. Rest of Europe
13.3.19.1. Overview
13.3.19.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.3.19.3. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.3.19.4. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.3.19.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.3.19.6. Rest of the Europe Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.3.19.7. Rest of the Europe Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.3.19.8. Rest of the Europe Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4. Asia Pacific (APAC)
13.4.1. Overview
13.4.2. Anticancer Drug Key Manufacturers in Asia Pacific
13.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.4.4. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.5. APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.7. APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.8. APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.9. APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.10. China
13.4.10.1. Overview
13.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.10.3. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.10.4. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.10.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.10.6. China Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.10.7. China Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.10.8. China Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.11. India
13.4.11.1. Overview
13.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.11.3. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.11.4. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.11.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.11.6. India Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.11.7. India Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.11.8. India Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.12. Japan
13.4.12.1. Overview
13.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.12.3. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.12.4. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.12.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.12.6. Japan Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.12.7. Japan Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.12.8. Japan Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.13. South Korea
13.4.13.1. Overview
13.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.13.3. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.13.4. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.13.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.13.6. South Korea Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.13.7. South Korea Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.13.8. South Korea Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.14. Australia
13.4.14.1. Overview
13.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.14.3. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.14.4. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.14.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.14.6. Australia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.14.7. Australia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.14.8. Australia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.15. Indonesia
13.4.15.1. Overview
13.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.15.3. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.15.4. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.15.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.15.6. Indonesia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.15.7. Indonesia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.15.8. Indonesia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.16. Thailand
13.4.16.1. Overview
13.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.16.3. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.16.4. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.16.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.16.6. Thailand Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.16.7. Thailand Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.16.8. Thailand Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.17. Philippines
13.4.17.1. Overview
13.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.17.3. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.17.4. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.17.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.17.6. Philippines Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.17.7. Philippines Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.17.8. Philippines Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.4.18. Rest of APAC
13.4.18.1. Overview
13.4.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.4.18.3. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.4.18.4. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.4.18.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.4.18.6. Rest of APAC Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.4.18.7. Rest of APAC Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.4.18.8. Rest of APAC Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5. Latin America (LATAM)
13.5.1. Overview
13.5.2. Anticancer Drug Key Manufacturers in Latin America
13.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.5.4. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.5. LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.7. LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.8. LATAM Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.9. LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5.10. Brazil
13.5.10.1. Overview
13.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.10.3. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.10.4. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.10.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.10.6. Brazil Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.10.7. Brazil Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.10.8. Brazil Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5.11. Mexico
13.5.11.1. Overview
13.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.11.3. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.11.4. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.11.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.11.6. Mexico Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.11.7. Mexico Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.11.8. Mexico Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5.12. Argentina
13.5.12.1. Overview
13.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.12.3. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.12.4. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.12.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.12.6. Argentina Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.12.7. Argentina Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.12.8. Argentina Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5.13. Colombia
13.5.13.1. Overview
13.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.13.3. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.13.4. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.13.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.13.6. Colombia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.13.7. Colombia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.13.8. Colombia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.5.14. Rest of LATAM
13.5.14.1. Overview
13.5.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.5.14.3. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.5.14.4. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.5.14.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.5.14.6. Rest of LATAM Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.5.14.7. Rest of LATAM Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.5.14.8. Rest of LATAM Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6. Middle East and Africa
13.6.1. Overview
13.6.2. Anticancer Drug Key Manufacturers in Middle East and Africa
13.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
13.6.4. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.5. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.6. Middle East and Africa Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.8. Middle East and Africa Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.9. Middle East and Africa Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.10. Saudi Arabia
13.6.10.1. Overview
13.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.10.3. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.10.4. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.10.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.10.6. Saudi Arabia Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.10.7. Saudi Arabia Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.10.8. Saudi Arabia Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.11. United Arab Emirates
13.6.11.1. Overview
13.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.11.3. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.11.4. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.11.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.11.6. United Arab Emirates Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.11.7. United Arab Emirates Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.11.8. United Arab Emirates Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.12. Israel
13.6.12.1. Overview
13.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.12.3. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.12.4. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.12.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.12.6. Israel Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.12.7. Israel Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.12.8. Israel Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.13. Turkey
13.6.13.1. Overview
13.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.13.3. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.13.4. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.13.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.13.6. Turkey Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.13.7. Turkey Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.13.8. Turkey Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.14. Algeria
13.6.14.1. Overview
13.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.14.3. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.14.4. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.14.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.14.6. Algeria Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.14.7. Algeria Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.14.8. Algeria Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.15. Egypt
13.6.15.1. Overview
13.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.15.3. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.15.4. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.15.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.15.6. Egypt Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.15.7. Egypt Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.15.8. Egypt Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
13.6.16. Rest of MEA
13.6.16.1. Overview
13.6.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
13.6.16.3. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
13.6.16.4. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
13.6.16.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
13.6.16.6. Rest of MEA Market Size and Forecast, By Distribution Channels, 2019 - 2032 (US$ Million)
13.6.16.7. Rest of MEA Market Size and Forecast, By Dosage Form, 2019 - 2032 (US$ Million)
13.6.16.8. Rest of MEA Market Size and Forecast, By End-Users, 2019 - 2032 (US$ Million)
14. Key Vendor Analysis- Anticancer Drug Industry
14.1. Competitive Benchmarking
14.1.1. Competitive Dashboard
14.1.2. Competitive Positioning
14.2. Company Profiles
14.2.1. Novartis
14.2.2. Pfizer
14.2.3. Merck & Co. (MSD)
14.2.4. Bristol Myers Squibb (BMS)
14.2.5. AstraZeneca
14.2.6. Roche/Genentech
14.2.7. Johnson & Johnson/Janssen
14.2.8. Sanofi
14.2.9. Eli Lilly & Co.
14.2.10. Takeda
14.2.11. Amgen
14.2.12. BeiGene
14.2.13. Regeneron
14.2.14. Bluebird Bio
14.2.15. Seagen
14.2.16. Moderna
14.2.17. Genmab
14.2.18. Incyte
14.2.19. Exelixis
14.2.20. Hutchmed / Chi-Med
14.2.21. Others
15. 360 Degree Analyst View
16. Appendix
16.1. Research Methodology
16.2. References
16.3. Abbreviations
16.4. Disclaimer
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ANTICANCER DRUG MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Novartis
- Pfizer
- Merck & Co. (MSD)
- Bristol Myers Squibb (BMS)
- AstraZeneca
- Roche/Genentech
- Johnson & Johnson/Janssen
- Sanofi
- Eli Lilly & Co.
- Takeda
- Amgen
- BeiGene
- Regeneron
- Bluebird Bio
- Seagen
- Moderna
- Genmab
- Incyte
- Exelixis
- Hutchmed / Chi-Med
- Others
GLOBAL ANTICANCER DRUG MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032
- Intravenous (IV)
- Subcutaneous
- Oral
- Topical / Localized
GLOBAL ANTICANCER DRUG MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032
- Chemotherapy
- Immunotherapy (Checkpoint inhibitors, CAR-T, TCR therapies)
- Monoclonal Antibodies / Biologics
- Hormone Therapy
- Targeted Therapy
- Others (Oncolytic viruses, combination therapies, adjuncts)
GLOBAL ANTICANCER DRUG MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Breast Cancer
- Lung Cancer
- Prostate Cancer
- Gastrointestinal Cancer
- Blood Cancer
- Gynaecologic Cancer
- Others
GLOBAL ANTICANCER DRUG MARKET, BY DISTRIBUTION CHANNELS- MARKET ANALYSIS, 2019 - 2032
- Online Pharmacy
- Hospital Pharmacy
- Retail Pharmacy
GLOBAL ANTICANCER DRUG MARKET, BY DOSAGE FORM- MARKET ANALYSIS, 2019 - 2032
- Solid (Tablets, Capsule)
- Injectable (Prefilled Syringes, Others)
- Liquid
- Others
GLOBAL ANTICANCER DRUG MARKET, BY END-USERS- MARKET ANALYSIS, 2019 - 2032
- Specialty Clinics
- Hospitals
- Homecare
- Others
GLOBAL ANTICANCER DRUG MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
